Marwan Fakih, Associate Director for Clinical Sciences at City of Hope, shared a post on X:
“Today, at GI ASCO, I had the privilege of presenting the results of R Phase 2 study of BOT +/- BAL in chemoresistant MSS CRC – an area in dire need of treatment options. BOT75/BAL240 ORR 19%, DCR 55%. BAL value confirmed. Majority study responses ongoing. Durable responses matter.”
More posts featuring Marwan Fakih.